Chugai Seiyaku Kabushiki Kaisha

The University of Tokyo

Toshiyuki Tsukaguchi

Hiroshi Sakamoto

Nobuo Shimma

Hidenori Takahashi

Nobuhiro Oikawa

Kazuo Hattori

Eisaku Mizuguchi

Kenji Morikami

Nobuya Ishii

Sawako Ozawa

Takehiro Okada

Osamu Kondoh

Tatsushi Kodama

Satoshi Niizuma

Fumio Watanabe

Satoshi Tanida

Hirosato Ebiike

Miyako Masubuchi

Masaki Shibata

Kohei Koyama

The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.

Combination drug

A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can he used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET. 

RET inhibitor

A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can be used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET. 

The present invention provides a compound represented by the formula (1):  

Heteroarylphenylurea derivative

The present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof: 

1-(2H)-isoquinolone derivative

It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents &#x2014;(O)&#x2014;R; R represents a C-Calkyl group or the like; n represents 0 or 1; X represents O or the like; R, Rand Rare independently selected from a hydrogen atom or C-Calkyl; or Rand Rmay join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.

Pyrazolopyridine and pyrrolopyridine multikinase inhibitors

The present invention provides a compound having high antitumor activity, which is useful for therapeutic and preventive agents effective for proliferative diseases such as cancer; a production method thereof; an intermediate compound useful for such production; and a pharmaceutical composition comprising such a compound. The present invention provides a compound represented by the formula (1): wherein X represents an aryl group or heteroaryl group which may be substituted, Cy represents a 4- to 7-membered monocyclic heterocyclic ring or a 8- to 10-membered condensed heterocyclic ring which may be substituted, and Z represents O, S, or NRa; or a prodrug thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutical and a pharmaceutical composition which comprise the compound.

Growing community of inventors

Kamakura, Japan

Toshiyuki Tsukaguchi